Immune checkpoint inhibitors (ICPIs) have transformed the treatment of lung cancer in the recent years. However, disruption in immune homeostasis produces a unique spectrum of side effects termed as immune-related adverse events (irAEs). Cutaneous irAE are the most prevalent toxicity from the ICPIs. While there have been descriptions of the cutaneous irAEs from ICPIs in melanoma patients,…
IASLC Member Registration Opens November 17, 2023 Abstract Submission Closes December 15, 2023 (23:59 MST) Abstract Notifications January 4, 2024 Conference in Santa Monica, California…
Event Time – (UTC-08:00) Pacific Time (US & Canada) Wednesday, February 21, 2024 Thursday, February 22, 2024 Friday, February 23, 2024 Saturday, February 24, 2024…
Dear Colleagues and Friends, The IASLC 2024 Targeted Therapies of Lung Cancer Meeting will take place February 21-24, 2024. This will be the final year the…
To explore the association of the effective dose to immune cells (EDIC) with disease control, lymphopenia, and toxicity in patients with non-small cel…
Original Article from The New England Journal of Medicine — Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Proton therapy may have a significant effect on decreasing dose to individual cardiovascular substructures compared with photon therapy. There was no significant difference in heart…
Original Article from The New England Journal of Medicine — Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Original Article from The New England Journal of Medicine — Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Original Article from The New England Journal of Medicine — Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Founded in 1972, the International Association for the Study of Lung Cancer (IASLC) is an international organization of more than 8,000 lung cancer specialists from…
